Association between Helicobacter pylori VacA antigens and gastric cancer depends on the detection method used: immunoblot versus neutralization of the vacuolating activity of VacA.
There are inconsistent findings on the association between Helicobacter pylori anti-VacA antibodies and gastric cancer (GC) risk. The lack of optimally sensitive and specific methods to detect anti-VacA antibodies may partly be responsible for this discrepancy. The aim of this study was to compare the association between GC and the presence of anti-VacA antibodies using two different detection methods. A secondary analysis of sera collected in a hospital-based case-control study in three geographical areas of Mexico was performed. Anti-VacA antibodies were determined by a neutralization assay and an immunoblot assay in serum samples of 203 histologically confirmed GC cases and 430 age- and sex-matched controls. H. pylori IgG status was determined by immunoblotting and H. pylori CagA status data was available for this study. Unconditional logistic regression models were used to estimate the association between anti-VacA antibodies and GC by histological type (diffuse and intestinal). Anti-VacA seroprevalence was higher using neutralization compared with immunoblotting: 68.5 vs 44.3 % for cases and 60.5 vs 44.2 % for controls. A significant association between anti-VacA antibodies and diffuse GC was found using neutralization [odds ratio (OR)=1.69, 95 % CI 1.08-2.66], but the association did not remain significant after adjusting for CagA status (OR 1.37, 95 % CI 0.81-2.32). No association between anti-VacA antibodies and GC was found when using immunoblotting. Thus, the association between anti-VacA antibodies and GC partly depends on the detection method used. These results do not support an independent role for VacA in GC risk in the presence of CagA seropositivity and strengthen the importance of CagA as a potential risk factor for GC.
National Institute of Public Health of Mexico. Av. Universidad No. 655, Col. Santa Ma. Ahuacatitlán, 62508 Cuernavaca, Morelos, Mexico.
Guadalupe
G
Ayala
National Institute of Public Health of Mexico. Av. Universidad No. 655, Col. Santa Ma. Ahuacatitlán, 62508 Cuernavaca, Morelos, Mexico.
Julia
J
Torres-Mena
National Institute of Public Health of Mexico. Av. Universidad No. 655, Col. Santa Ma. Ahuacatitlán, 62508 Cuernavaca, Morelos, Mexico.
Lizbeth
L
López-Carrillo
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology / Q000633:toxicity*; D016022:Case-Control Studies; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D016480:Helicobacter pylori / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D013274:Stomach Neoplasms / Q000139:chemically induced* / Q000276:immunology / Q000382:microbiology / Q000473:pathology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D007074:Immunoglobulin G; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori